Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers August 16, 2022Kalyn DabbsPress Releases Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial Read More
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer August 15, 2022Kalyn DabbsAcclaim 2Press Releases Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial Read More